Related Experiment Videos
Combination chemotherapy for metastatic breast cancer
Jean-Marc A Nabholtz1, David M Reese, Mary-Ann Lindsay
1University of California, Los Angeles, Peter Ueberroth Building 3360B, 10945 Le Conte Avenue, Los Angeles, CA 90095-7077, USA. jean-marc.nabholtz@bcirg.com
Abstract:
Despite more than four decades of effort, the improvement in survival in metastatic breast cancer has been modest. Recently, however, new drugs such as the taxanes have emerged as pivotal agents in the treatment of metastatic disease and they are now being investigated in the adjuvant setting. In addition, the introduction of molecularly targeted therapies such as trastuzumab provides a new paradigm for the development of biologic treatments. The incorporation of trastuzumab into new combination regimens based on potential molecular synergies is a focus of current research.
Insights
Despite modest survival improvements in metastatic breast cancer, new treatments like taxanes and targeted therapies such as trastuzumab offer new hope. Research is exploring combination regimens for better outcomes.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Metastatic breast cancer treatment has seen limited survival gains over four decades.
- Taxanes represent a significant advancement in managing metastatic breast cancer.
- Molecularly targeted therapies, like trastuzumab, are revolutionizing biologic treatment approaches.
Purpose of the Study:
- To review recent advancements in metastatic breast cancer therapy.
- To highlight the role of taxanes and targeted therapies.
- To discuss the potential of combination regimens involving trastuzumab.
Main Methods:
- Literature review of recent clinical studies and treatment guidelines.
- Analysis of the efficacy of taxanes in metastatic and adjuvant settings.
- Examination of trastuzumab's mechanism of action and clinical applications.
Main Results:
- Taxanes have become key agents in metastatic breast cancer treatment.
- Trastuzumab offers a new paradigm for biologic therapies.
- Investigating molecularly targeted therapies in combination regimens is a critical research area.
Conclusions:
- Recent drug developments, including taxanes and trastuzumab, are improving metastatic breast cancer management.
- Combination therapies incorporating trastuzumab show promise for enhanced patient survival.
- Continued research into molecular synergies is essential for advancing breast cancer treatment.